Abivax Overview
Compare Abivax's DCF valuation ($7.8) to today's market price.
Get informed when a big investor buys or sells
+ Follow$7.84
Overvalued by 93.2% based on the discounted cash flow analysis.
Abivax (ABVX) currently reports a DCF fair value of $7.8. Use the charts on this page to explore Abivax's DCF fair value history and peer comparisons.
Abivax's discounted cash flow (DCF) fair value estimate is $7.8, about 93.2% overvalued versus the current market price. DCF models project future free cash flows and discount them back to today — so the result depends on growth, margin, and discount-rate assumptions. Use it as one valuation lens alongside multiples and peer checks on Stockcircle.
Start with the current DCF fair value of $7.8, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Abivax, and consider following ABVX for alerts when major investors trade the stock.
Abivax is classified in the Healthcare sector. On DCF fair value, it currently shows $7.8. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ABVX with unrelated industries.
